Truist Financial Corp raised its stake in shares of Abcam plc (NASDAQ:ABCM – Get Rating) by 42.3% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 37,827 shares of the company’s stock after acquiring an additional 11,243 shares during the quarter. Truist Financial Corp’s holdings in Abcam were worth $567,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. Brown Advisory Inc. increased its stake in shares of Abcam by 8.6% in the second quarter. Brown Advisory Inc. now owns 3,168,283 shares of the company’s stock worth $45,813,000 after purchasing an additional 252,025 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Abcam by 26.3% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,553,124 shares of the company’s stock worth $22,458,000 after purchasing an additional 323,670 shares during the period. DF Dent & Co. Inc. increased its stake in shares of Abcam by 9.6% in the second quarter. DF Dent & Co. Inc. now owns 816,673 shares of the company’s stock worth $11,809,000 after purchasing an additional 71,691 shares during the period. Citadel Advisors LLC increased its stake in shares of Abcam by 20.4% in the second quarter. Citadel Advisors LLC now owns 130,697 shares of the company’s stock worth $1,890,000 after purchasing an additional 22,182 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Abcam by 87.3% in the second quarter. Millennium Management LLC now owns 287,629 shares of the company’s stock worth $4,159,000 after purchasing an additional 134,055 shares during the period. 13.91% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft started coverage on Abcam in a research note on Tuesday, December 13th. They issued a “hold” rating on the stock.
Abcam Price Performance
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- CVS Health is Growing into an Integrated Healthcare Organization
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.